{"analyses":[{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.13","estimateComment":"A hazard ratio \\<1 favours Osimertinib 80 mg","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.277","paramType":"Hazard Ratio (HR)","paramValue":"0.87","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.5","upperLimit":"31.5","value":"26.8"},{"groupId":"OG001","lowerLimit":"20.2","upperLimit":"28.8","value":"22.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"140"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Daily single dose of Osimertinib 80mg","id":"OG000","title":"Osimertinib 80mg"},{"description":"Platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of randomization until time of final OS analysis, a median follow-up of 43 months","title":"Secondary: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}